Pages that link to "Q46801526"

The following pages link to Pooled analysis of diarrhea events in patients with cancer treated with lapatinib (Q46801526):

Displaying 37 items.

• Current combination chemotherapy regimens for metastatic breast cancer (Q33516194) (← links)
• Development of the rat model of lapatinib-induced diarrhoea. (Q33999288) (← links)
• Safety Profile and Clinical Recommendations for the Use of Lapatinib (Q34096239) (← links)
• Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib (Q34241118) (← links)
• Targeted treatment of advanced and metastaticbreast cancer with lapatinib. (Q34363419) (← links)
• Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. (Q34417920) (← links)
• Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study (Q35005762) (← links)
• Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis (Q35077315) (← links)
• Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea (Q36384340) (← links)
• Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer. (Q36483151) (← links)
• Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea (Q36875372) (← links)
• A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer (Q37143133) (← links)
• Effect of age on drug metabolism in women with breast cancer (Q37325560) (← links)
• Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients (Q37491455) (← links)
• Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer (Q37605777) (← links)
• Lapatinib in metastatic breast cancer. (Q37622978) (← links)
• Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. (Q37628693) (← links)
• Safety profile of new anticancer drugs. (Q37696502) (← links)
• Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel (Q37765198) (← links)
• Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer (Q37771017) (← links)
• Prevention and management of major side effects of targeted agents in breast cancer (Q37785387) (← links)
• Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer (Q37929417) (← links)
• Tumor control versus adverse events with targeted anticancer therapies (Q37969899) (← links)
• Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). (Q37999119) (← links)
• Diarrhea associated with afatinib: an oral ErbB family blocker (Q38090739) (← links)
• Strategies for dealing with fraud in clinical trials (Q38551076) (← links)
• Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer (Q39147161) (← links)
• Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. (Q42598708) (← links)
• Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study (Q42618816) (← links)
• Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies (Q44692841) (← links)
• Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. (Q54335490) (← links)
• Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. (Q54389879) (← links)
• Gastrointestinal toxicities of novel agents in cancer therapy. (Q54719163) (← links)
• Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients (Q59390248) (← links)
• Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib (Q61446600) (← links)
• Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial (Q64094063) (← links)
• A Phase I Study of Capecitabine, Oxaliplatin, and Lapatinib in Metastatic or Advanced Solid Tumors (Q84189195) (← links)